Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?

Sarah L. Savaridas (Lead / Corresponding author), Yee Ting Sim, Sarah J. Vinnicombe, Colin A. Purdie, Alastair M. Thompson, Andy Evans

Research output: Contribution to journalArticle

3 Citations (Scopus)
69 Downloads (Pure)

Abstract

Background: Increasing numbers of breast cancer patients receive neoadjuvant chemotherapy (NACT). We seek to investigate whether baseline mammographic and ultrasound features are associated with complete pathological response (pCR) after NACT.

Methods: A database of NACT patients was reviewed. Baseline imaging parameters assessed were ultrasound: posterior effect; echo pattern; margin and lesion diameter; mammography: spiculation and microcalcification. Core biopsy grade and immunophenotype were documented. Data were analysed for the whole study group and by immunophenotype.

Results: Of the 222 cancers, 83 (37%) were triple negative (TN), 61 (27%) ER positive/HER-2 negative and 78 (35%) HER-2 positive. A pCR occurred in 46 of 222 cancers (21%). For the whole group, response was associated with high core biopsy grade (grade 3 vs. grade 1 or 2) (26% vs. 9%, p = 0.0044), absence of posterior shadowing on ultrasound (26% vs. 10%, p <  0.001) and the absence of mammographic spiculation (26 vs. 6%, p <  0.001). Within the HER-2 positive group; the absence of shadowing and spiculation remained highly associated with pCR, in addition to small ultrasound size (AUC = 0.71, p < 0.001) and the absence of microcalcification (39% vs. 21%, p < 0.02). On multivariable analysis absence of spiculation and core grade remained significant for the whole cohort, size and absence of spiculation remained significant for HER-2 positive tumours. No feature predicted pCR in TN tumours.

Conclusion: A pCR is less likely when there is mammographic spiculation. Small ultrasound size is associated with pCR in HER-2 positive tumours. These findings may be helpful when discussing NACT and surgical options with patients.

Trial registration: UK Clinical Trials Gateway: registration number 16712.

Original languageEnglish
Article number67
Pages (from-to)1-7
Number of pages7
JournalCancer Imaging
Volume19
Issue number1
DOIs
Publication statusPublished - 21 Oct 2019

Keywords

  • Breast carcinoma
  • Mammography
  • Neoadjuvant chemotherapy
  • Pathological complete response
  • Ultrasound

Fingerprint Dive into the research topics of 'Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?'. Together they form a unique fingerprint.

  • Profiles

    No photo of Andrew Evans

    Evans, Andrew

    Person: Academic

    Cite this